Effect of sodium fluoride, inorganic phosphate, and oxymetholone therapies in osteoporosis: a six-year progress report.
Elderly osteoporotic males treated with sodium fluoride or inorganic phosphate for 4 years plus 2 years of follow-up observations exhibited a mean but not significant decrease in the rate of bone mass loss in comparison with those receiving oxymetholone or a placebo. No hip fractures occurred in the patients who received fluoride, while 11 hip fractures occurred in the patients in the phosphate, oxymetholone, and control groups. Because the densitometric trends and fracture incidence are impressive, the progress of all subjects will be followed for an additional 4 years.
D000368:Aged; D003720:Densitometry; D005459:Fluorides / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D010110:Oxymetholone / Q000627:therapeutic use*; D010710:Phosphates / Q000627:therapeutic use*; D012969:Sodium Fluoride / Q000627:therapeutic use*
D010710:Phosphates; D012969:Sodium Fluoride; D010110:Oxymetholone; D005459:Fluorides